|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02666 UNI MEDICAL
Nominal 
6.060 +0.010 (+0.165%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 7,580,699 | 15.865% | 13,663,485 | 13,650,203 | 12,073,172 | 9,914,273 |
| Cost of Sales | (4,977,637) | 16.331% | (9,071,645) | (9,078,344) | (7,578,878) | (5,714,834) |
| Gross Profit | 2,603,062 | 14.985% | 4,591,840 | 4,571,859 | 4,494,294 | 4,199,439 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (48,492) | -55.546% | (322,980) | (192,099) | (307,139) | (318,235) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | (519) | (1,624) | (1,154) | (942) | |
| Share of Results of Asso. & JCEs | (904) | -- | 26,564 | 6,380 | 13,462 | 13,865 | |
| Profit / (Loss) before Taxation | 1,741,315 | 7.577% | 2,907,119 | 2,866,213 | 2,703,274 | 2,691,808 | |
| Taxation | (406,088) | 10.801% | (648,785) | (667,141) | (617,326) | (661,339) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (76,421) | -3.520% | (154,377) | (88,735) | (126,128) | (82,739) | |
| Others | (30,673) | -14.151% | (72,217) | (89,419) | (71,403) | (112,497) | |
| Profit / (Loss) Attributable to Shareholders | 1,228,133 | 7.993% | 2,031,740 | 2,020,918 | 1,888,417 | 1,835,233 | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 17,327 | -- | (4,797) | (45,075) | (38,517) | (27,564) |
| Depreciation & Amortisation | 342,648 | 30.750% | 602,257 | 508,665 | 442,049 | 319,464 |
| Directors' Emoluments | -- | -- | 8,786 | 13,785 | 14,631 | 12,354 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 65.000 | 8.333% | 107.000 | 107.000 | 100.000 | 99.000 |
| DPS (cts) | 0.000 | -- | 32.300 | 31.740 | 29.788 | 29.264 |
| Dividend Payout Ratio (%) | -- | -- | 30.187% | 29.664% | 29.788% | 29.559% |
| Cash flow per share ($) | -- | -- | 0.602 | 2.640 | 1.074 | (0.753) |
| NBV per share ($) | 9.337 | -- | 9.058 | 8.248 | 7.351 | 6.888 |
| Remarks: | Real time quote last updated: 29/08/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,228,133 |
| %Change | 7.993% |
| EPS / (LPS) | RMB 0.650 |
| NBV Per Share (¥) | RMB 9.337 |